Real-life data of azacitidine-venetoclax combination in acute myeloid leukemia patients: a single center experience

Tuba Bulduk; Melda Cömert; Ebru Kılıç; Selim Sayın; Murat Yıldırım; Meltem Aylı

Makale detayları

Real-life data of azacitidine-venetoclax combination in acute myeloid leukemia patients: a single center experience

Yazarlar:

Tuba Bulduk | Melda Cömert | Ebru Kılıç | Selim Sayın | Murat Yıldırım | Meltem Aylı

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Hematoloji | Klinik Onkoloji | Kemoterapi

Dergi:

Journal of Health Sciences and Medicine Vol.6 Issue 6, pp.1237-1243

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001303051

pISSN:

2636-8579

Anahtar kelimeler:

Özet:

 Aims: To evaluate real-life data on the efficacy and safety of Venetoclax Ven therapy used in combination with hypomethylating agent HMA in patients with acute myeloid leukemia AML. Methods: The records of newly diagnosed, relapsed or refractory RR AML patients over 18 years of age who were planned to be treated with Azacitidine AZA combined with Ven because they were not suitable for intensive chemotherapy and patients who received AZA combined with Ven maintenance therapy after achieving remission were retrospectively analyzed. The standard protocol for patients is subcutaneous or intravenous AZA 75 mgm2 on days 1-7 every 28 days  oral Ven treatment 100-400 mgday for 28 days. The treatment response rates, survival times, and side effect profiles of 18 newly diagnosed patients, 12 RR patients, and 4 patients receiving AZAVen as maintenance treatment between January 2021 and March 2022 were evaluated. Results: It was found that 8 of the 34 patients 23.5 who were examined in the present study died before the first response could be evaluated. When the response rates were evaluated, complete response CR or complete remission with incomplete blood count recovery CRi CRCRi was found to be 61 in the group receiving AZAVen in the first line, and CRCRi was 50 in the group receiving AZAVen because of RR AML. In the group receiving AZAVen in the first line, the average Overall Survival OS was 8.00 months 95 CI: 1.58-14.41, and 7.00 months in the RR group 95 CI: 1.78-12, 21. All patients in the group receiving AZAVen for maintenance purposes were alive and the median follow-up period was 12.506.02 months in this group MeanSD. The most common side effect was neutropenia, and the most common cause of death was disease progression. Conclusion: In AML patients ineligible for intensive treatment due to advanced age or comorbidities, real-life data of AZAVen therapy with effective CRCRi rates and a manageable spectrum of side effects promise hope.

 Aims: To evaluate real-life data on the efficacy and safety of Venetoclax Ven therapy used in combination with hypomethylating agent HMA in patients with acute myeloid leukemia AML. Methods: The records of newly diagnosed, relapsed or refractory RR AML patients over 18 years of age who were planned to be treated with Azacitidine AZA combined with Ven because they were not suitable for intensive chemotherapy and patients who received AZA combined with Ven maintenance therapy after achieving remission were retrospectively analyzed. The standard protocol for patients is subcutaneous or intravenous AZA 75 mgm2 on days 1-7 every 28 days  oral Ven treatment 100-400 mgday for 28 days. The treatment response rates, survival times, and side effect profiles of 18 newly diagnosed patients, 12 RR patients, and 4 patients receiving AZAVen as maintenance treatment between January 2021 and March 2022 were evaluated. Results: It was found that 8 of the 34 patients 23.5 who were examined in the present study died before the first response could be evaluated. When the response rates were evaluated, complete response CR or complete remission with incomplete blood count recovery CRi CRCRi was found to be 61 in the group receiving AZAVen in the first line, and CRCRi was 50 in the group receiving AZAVen because of RR AML. In the group receiving AZAVen in the first line, the average Overall Survival OS was 8.00 months 95 CI: 1.58-14.41, and 7.00 months in the RR group 95 CI: 1.78-12, 21. All patients in the group receiving AZAVen for maintenance purposes were alive and the median follow-up period was 12.506.02 months in this group MeanSD. The most common side effect was neutropenia, and the most common cause of death was disease progression. Conclusion: In AML patients ineligible for intensive treatment due to advanced age or comorbidities, real-life data of AZAVen therapy with effective CRCRi rates and a manageable spectrum of side effects promise hope.

 Aims: To evaluate real-life data on the efficacy and safety of Venetoclax Ven therapy used in combination with hypomethylating agent HMA in patients with acute myeloid leukemia AML. Methods: The records of newly diagnosed, relapsed or refractory RR AML patients over 18 years of age who were planned to be treated with Azacitidine AZA combined with Ven because they were not suitable for intensive chemotherapy and patients who received AZA combined with Ven maintenance therapy after achieving remission were retrospectively analyzed. The standard protocol for patients is subcutaneous or intravenous AZA 75 mgm2 on days 1-7 every 28 days  oral Ven treatment 100-400 mgday for 28 days. The treatment response rates, survival times, and side effect profiles of 18 newly diagnosed patients, 12 RR patients, and 4 patients receiving AZAVen as maintenance treatment between January 2021 and March 2022 were evaluated. Results: It was found that 8 of the 34 patients 23.5 who were examined in the present study died before the first response could be evaluated. When the response rates were evaluated, complete response CR or complete remission with incomplete blood count recovery CRi CRCRi was found to be 61 in the group receiving AZAVen in the first line, and CRCRi was 50 in the group receiving AZAVen because of RR AML. In the group receiving AZAVen in the first line, the average Overall Survival OS was 8.00 months 95 CI: 1.58-14.41, and 7.00 months in the RR group 95 CI: 1.78-12, 21. All patients in the group receiving AZAVen for maintenance purposes were alive and the median follow-up period was 12.506.02 months in this group MeanSD. The most common side effect was neutropenia, and the most common cause of death was disease progression. Conclusion: In AML patients ineligible for intensive treatment due to advanced age or comorbidities, real-life data of AZAVen therapy with effective CRCRi rates and a manageable spectrum of side effects promise hope.

 Aims: To evaluate real-life data on the efficacy and safety of Venetoclax Ven therapy used in combination with hypomethylating agent HMA in patients with acute myeloid leukemia AML. Methods: The records of newly diagnosed, relapsed or refractory RR AML patients over 18 years of age who were planned to be treated with Azacitidine AZA combined with Ven because they were not suitable for intensive chemotherapy and patients who received AZA combined with Ven maintenance therapy after achieving remission were retrospectively analyzed. The standard protocol for patients is subcutaneous or intravenous AZA 75 mgm2 on days 1-7 every 28 days  oral Ven treatment 100-400 mgday for 28 days. The treatment response rates, survival times, and side effect profiles of 18 newly diagnosed patients, 12 RR patients, and 4 patients receiving AZAVen as maintenance treatment between January 2021 and March 2022 were evaluated. Results: It was found that 8 of the 34 patients 23.5 who were examined in the present study died before the first response could be evaluated. When the response rates were evaluated, complete response CR or complete remission with incomplete blood count recovery CRi CRCRi was found to be 61 in the group receiving AZAVen in the first line, and CRCRi was 50 in the group receiving AZAVen because of RR AML. In the group receiving AZAVen in the first line, the average Overall Survival OS was 8.00 months 95 CI: 1.58-14.41, and 7.00 months in the RR group 95 CI: 1.78-12, 21. All patients in the group receiving AZAVen for maintenance purposes were alive and the median follow-up period was 12.506.02 months in this group MeanSD. The most common side effect was neutropenia, and the most common cause of death was disease progression. Conclusion: In AML patients ineligible for intensive treatment due to advanced age or comorbidities, real-life data of AZAVen therapy with effective CRCRi rates and a manageable spectrum of side effects promise hope.

Makale detayları

Real-life data of azacitidine-venetoclax combination in acute myeloid leukemia patients: a single center experience

Yazarlar: Tuba Bulduk | Melda Cömert | Ebru Kılıç | Selim Sayın | Murat Yıldırım | Meltem Aylı

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Hematoloji | Klinik Onkoloji | Kemoterapi

Dergi: Journal of Health Sciences and Medicine Vol.6 Issue 6, pp.1237-1243

Belge Tipi: Makale

Yayın Tarihi: 10/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001303051

pISSN: 2636-8579

acute myeloid leukemia

azacitidine

venetoclax

chemoterapy

Sayı

Yazarlar:

Tuba Bulduk | Melda Cömert | Ebru Kılıç | Selim Sayın | Murat Yıldırım | Meltem Aylı

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Hematoloji | Klinik Onkoloji | Kemoterapi

Dergi:

Journal of Health Sciences and Medicine Vol.6 Issue 6, pp.1237-1243

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001303051

pISSN:

2636-8579